Skip to main content
Premium Trial:

Request an Annual Quote

Phenomics Health Acquires Precera Pharmacometabolomic Technology

NEW YORK — Bioinformatics firm Phenomics Health said today that it has acquired the pharmacometabolomic technology portfolio of Precera Bioscience.

Terms of the deal were not disclosed.

The patented technology, called PrecisMed, is designed to analyze blood from a finger prick to detect, measure, and assess over 200 medications in a patient's bloodstream. Ann Arbor, Michigan-based Phenomics said it will incorporate the technology into its own pharmacogenomics platform for reviewing a patient's potential and actual response to medications.

"Our newly enhanced platform integrates Phenomics Health's disease-drug response network discoveries and patient pharmacometabolomic profiles to enhance the precision and predictability of medication selection," Phenomics Cofounder, CSO, and CTO Brian Athey said in a statement. "The information gathered through its use could change the direction of how clinicians prescribe and manage medications, greatly improving a patient's response."